Revolutionising colonoscopy - New Product Introduction of a painless magnetic endoscope

早期发现和治疗对提高患者的生活质量和结肠疾病的存活率至关重要。这些疾病包括癌症(每年导致全球881000多人死亡)和炎症性肠道疾病(影响数以百万计的人并增加患结直肠癌的风险)。使用柔性内窥镜进行标准结肠镜检查，是目前识别疾病和进行小手术干预的最佳方法。不幸的是，它也有显著的缺点：患者痛苦，操作员需要长时间的培训，以及技术、人员配备和专用基础设施的高昂成本。这有几个影响，最严重的是有限的手术可获得性，导致对结肠镜检查的需求不受限制，以及巨大的疾病和经济负担。这以不同的方式表现出来；在英国，估计有25%的患者等待4周以上才进行结肠镜检查，超过十分之一的人即使在家中检测呈阳性也没有参加结肠镜检查。美国预防服务工作组最近的指导方针建议从45岁开始筛查结肠镜检查，而不是50岁，这加剧了这种情况，仅在美国，潜在的筛查人口就增加到4400万人。阿特拉斯内窥镜旨在通过引入“REN”平台使结肠镜检查发生革命性变化，这是一个由机器人和可回收的一次性内窥镜组成的磁性结肠镜系统。我们的使命是通过使结肠镜检查更容易为人们所接受来拯救生命。我们将通过改进传统柔性内窥镜的缺点来做到这一点。经过15年的学术研究、30多篇同行评议的论文(包括《自然》和《科学》杂志)、广泛的临床前测试和创建一个衍生产品，Atlas Endoscope已经准备好将这些研究转化为产品，创造在医院有效和安全地部署REN所需的技术，以造福患者、临床医生和更广泛的医疗系统。这笔赠款资金对于提高REN的技术成熟度、为该系统的安全临床使用做好准备并使Atlas内窥镜对投资者、利益相关者和更广泛的英国经济更具吸引力将是至关重要的。阿特拉斯内窥镜致力于在英国发展业务，创造就业机会，吸引国际投资并创造可观的收入。

Early detection and treatment are crucial to improve patient quality-of-life and survival from colorectal diseases. These include cancer (which accounts for more than 881000 deaths annually worldwide) and inflammatory bowel diseases (which affect millions of individuals and increase risk of colorectal cancer). Standard colonoscopy, performed using a flexible endoscope, is currently the best method to identify disease and perform minor surgical interventions. Unfortunately, it comes with notable drawbacks: pain for the patient, long training required for operators and high costs from the technology, staffing & dedicated infrastructure. This has several impacts, the most serious being limited procedure accessibility that is resulting in uncurbed demand for colonoscopy and enormous disease and economic burden. This manifests in different ways; in the UK, an estimated 25% of patients wait more than 4 weeks to have their colonoscopy and more than 1 in 10 individuals are not attending colonoscopies even if tested positive by at-home tests. This is exacerbated by recent US Preventive Services Task Force guidelines recommending screening colonoscopy to begin at 45 instead of 50 years of age, increasing the potential screening population to 44 million individuals, in the US alone. Atlas Endoscopy aims at revolutionising colonoscopy by introducing the "REN" platform - a magnetic colonoscopy system composed of a robot and recyclable single-use endoscope.Our mission is to save lives by making colonoscopy more accessible to the population. We will do this by improving on the drawbacks of conventional flexible endoscopes. After 15 years of academic research, more than 30 peer reviewed papers (including Nature and Science), extensive pre-clinical testing and the creation of a spin-off, Atlas Endoscopy is ready to transform that research into a product, creating the technology required to deploy REN effectively and safely in hospitals for the benefit of patients, clinicians and the wider healthcare system. This grant funding will be essential to increase the technology maturity of REN, preparing the system for safe clinical use and making Atlas Endoscopy even more attractive to investors, stakeholders and the wider UK economy. Atlas Endoscopy is committed to grow the business in the UK, create jobs, attract international investment and generate significant revenue.